Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 196,000
- Avg volume
- 208,710
- Day's range
- $0.23 – $0.27
- Shares out
- —
- Stochastic %K
- 51%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Charlotte's Web Holdings, Inc. engages in the farming, manufacturing, marketing, and sale of hemp-derived cannabidiol (CBD) and botanical-based wellness products in the United States. The company offers full-spectrum hemp extract oil tinctures, such as liquid products; gummies; capsules; soft-gels; CBD topical creams and lotions; broad-spectrum botanical CBD; functional mushroom gummies; and pet products. Its product...
Show more
Charlotte's Web Holdings, Inc. engages in the farming, manufacturing, marketing, and sale of hemp-derived cannabidiol (CBD) and botanical-based wellness products in the United States. The company offers full-spectrum hemp extract oil tinctures, such as liquid products; gummies; capsules; soft-gels; CBD topical creams and lotions; broad-spectrum botanical CBD; functional mushroom gummies; and pet products. Its products contain naturally occurring phytocannabinoids, including CBD, cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), terpenes, flavonoids, and other beneficial hemp compounds. The company markets its products under the Charlotte's Web, Brightside, CBD Clinic, and CBD Medic brands. It distributes its products through its e-commerce website, third-party e-commerce websites, distributors, retailers, and healthcare practitioners. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Louisville, Colorado.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 720 484 8930
- Website
- https://www.charlottesweb.com
- Address
- 700 Tech Court, Louisville, United States
Latest news
No headlines yet.